Connection

José Aguado to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications José Aguado has written about Cost-Benefit Analysis.
José Aguado
Connection Strength
0.094
Cost-Benefit Analysis
  1. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. Eur J Clin Microbiol Infect Dis. 2019 Jun; 38(6):1105-1111.
    View in: PubMed
    Score: 0.094
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.